0001104659-24-034565.txt : 20240314 0001104659-24-034565.hdr.sgml : 20240314 20240314170125 ACCESSION NUMBER: 0001104659-24-034565 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240312 FILED AS OF DATE: 20240314 DATE AS OF CHANGE: 20240314 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: TAGLIAFERRI MARY CENTRAL INDEX KEY: 0001323304 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38650 FILM NUMBER: 24751142 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Y-mAbs Therapeutics, Inc. CENTRAL INDEX KEY: 0001722964 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 474619612 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 230 PARK AVENUE STREET 2: SUITE 3350 CITY: NEW YORK STATE: NY ZIP: 10169 BUSINESS PHONE: 212-847-9841 MAIL ADDRESS: STREET 1: 230 PARK AVENUE STREET 2: SUITE 3350 CITY: NEW YORK STATE: NY ZIP: 10169 4 1 tm248257-5_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-03-12 0 0001722964 Y-mAbs Therapeutics, Inc. YMAB 0001323304 TAGLIAFERRI MARY C/O Y-MABS THERAPEUTICS, INC. 230 PARK AVENUE, SUITE 3350 NEW YORK NY 10169 1 0 0 0 0 Common Stock 2024-03-12 4 A 0 4660 0 A 4660 D Stock Option (right to buy) 16.09 2024-03-12 4 A 0 27900 0 A 2034-03-12 Common Stock 27900 27900 D Represents 4,660 restricted stock units ("RSUs") granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each RSU represents a contingent right to receive one share of Common Stock on the vesting date of the RSUs. The RSUs vest in equal quarterly installments over a three-year period measured from three months following March 12, 2024, subject to the Reporting Person's continued service through each applicable vesting date. Stock options granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. The stock option shall vest and become exercisable in equal monthly installments over a three-year period measured from one month following March 12, 2024, subject to the Reporting Person's continued service through each applicable vesting date. /s/ John LaRocca, Attorney-in-Fact 2024-03-14